Skip to content
Peptigraph home

CJC-1295 + Ipamorelin and IGF-1 LR3 Together: What Is Known

CJC-1295 + Ipamorelin and IGF-1 LR3 taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH + GHRP blendNot FDA approved · research blendCJC-1295 + IpamorelinUnapproved blend of CJC-1295 (no DAC) and ipamorelin; an FDA Drugs@FDA search for the CJC-1295 component returned no matches, so no approved product was found.[12]Growth hormoneIGF-1 analogNot FDA approved · research chemicalIGF-1 LR3IGF-1 LR3, a long-acting IGF-1 analog with no published human trial; in rats it was 2.5 to 3 times more potent than IGF-I at restoring growth.[13]Growth hormone
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 1 result, 2 Oct 2026).

Neither is FDA approved for use in people, and we have no sourced data on combining them.
Each component

Side by side

Showing 10 of 12 fields where the two differ. Category, PCAC vote, Jul 2026 are the same or both unknown.

FieldCJC-1295 + IpamorelinIGF-1 LR3
ClassGHRH + GHRP blendIGF-1 analog
Also calledCJC/IpaLR3
FDA statusNot FDA approved · research blendNot FDA approved · research chemical
WADAProhibited by WADA (S2.2.4)Both components are named in S2.2.4 (CJC-1295 as a GHRH analogue, ipamorelin as a secretagogue), so the blend is prohibited at all times.Prohibited by WADA (S2.3)IGF-1 and its analogues (LR3 is an IGF-1 analogue) are prohibited in S2.3, at all times.
Anti-doping detection
  • After nasal dosing, ipamorelin metabolites were still found in urine after the parent drug was gone (samples were collected for 2 days).PMID 25869809
None reportedanti-doping literature, as of 2 Oct 2026
Half-lifeIpamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658563 min half-life in wound fluid (versus 872 min for IGF-I)wound chamber (rat) (rat) · The American journal of physiology 1999, PMID 10198302
Evidence strengthHuman RCT evidence, 4 of 4Ipamorelin: International journal of colorectal disease 2014, PMID 25331030Human observational evidence, 3 of 4Strongest: Growth hormone & IGF research 2010, PMID 20675162
Human studies we summarised6 human (3 randomized or controlled) of 19 summarised, across ingredients1 human (0 randomized or controlled) of 12 summarised
Typical study doses
Vial sizes sold10 mg0.1 mg, 1 mg
Related tools

CJC-1295 + Ipamorelin vs IGF-1 LR3

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

IGF-1 LR3 has no human trials

The effects of IGF-1 LR3 in humans have not been described; a case report of a vial containing a His-tagged LR3 concluded the product may be a by-product of biochemical studies rather than made for injection.[7]

In guinea pigs, LR3 enlarged some organs without stimulating overall growth.[14]

In pigs, a short LR3 infusion lowered growth hormone and the animals' own IGF-I and insulin.[15]

The blend is the GH-releasing side of the axis

In healthy adults, subcutaneous CJC-1295 produced sustained, dose-dependent rises in GH and IGF-I and was relatively well tolerated, particularly at 30 or 60 microg/kg.[5]

A PubMed search on 2 Oct 2026 for the CJC-1295 plus ipamorelin blend with IGF-1 LR3 matched 1 record, a review of performance peptides in the GH-IGF1 axis, not a trial.

Calculated from pubmed query (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab]))); records matched 1; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date

That review's stated aim is to contrast peer-reviewed evidence with online self-administration protocols, and it describes tiers down to a complete absence of human studies.[16]

The same review lists reported adverse effects of the class, including fluid retention and dysglycaemia.[16]

Regulatory and sport status

WADA's list covers IGF-1 and its analogues.[1]

FDA lists no approved IGF-1 LR3 product.[17]

The FDA safety note on CJC-1295 lists a raised heart rate and systemic vasodilation.[18]

Common questions

Can you stack IGF-1 LR3 with CJC-1295 and ipamorelin?

No study of the combination turned up. The LR3 papers cited here are two animal studies and a case report of a product vial.[7]

Is IGF-1 LR3 safe?

The effects of LR3 in people have not been described. In pigs, a short infusion cut the animals' own GH by 23% and kept their IGF-I and insulin low.[15]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
  3. 3Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  4. 4Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  5. 5Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  6. 6Clearance of IGFs and insulin from wounds: effect of IGF-binding protein interactions.The American journal of physiology · 1999PMID 10198302Accessed 2 Oct 2026
  7. 7Detection of His-tagged Long-R³-IGF-I in a black market product.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2010PMID 20675162Accessed 2 Oct 2026
  8. 8IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.American journal of physiology. Endocrinology and metabolism · 2025PMID 39679943Accessed 2 Oct 2026
  9. 9Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.Journal of Alzheimer's disease : JAD · 2025PMID 39610283Accessed 2 Oct 2026
  10. 10Insulin-like growth factor-I and analogues increase growth in artificially-reared neonatal pigs.The British journal of nutrition · 2002PMID 12067429Accessed 2 Oct 2026
  11. 11PubMed search: (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab])))PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  13. 13Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects.The Biochemical journal · 1993PMID 7683875Accessed 2 Oct 2026
  14. 14Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig.The Journal of endocrinology · 1995PMID 7561636Accessed 2 Oct 2026
  15. 15Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs.The Journal of endocrinology · 1997PMID 9488001Accessed 2 Oct 2026
  16. 16The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
  17. 17Drugs@FDA (openFDA) search: active ingredient "IGF-1 LR3"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  18. 18Official web pageOfficial web page · web page

Found an error? Report a correction.